规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
体外活性:雷诺嗪选择性抑制晚期 I(Na),减少 [Na(+)](i) 依赖性钙超载,并减轻与心肌细胞缺血/再灌注和心力衰竭相关的心室复极和收缩力异常。在狗的左心室肌细胞中,雷诺嗪以浓度依赖性方式显着且可逆地缩短 0.5 Hz 或 0.25 Hz 刺激的肌细胞的动作电位持续时间 (APD)。 5 和 10 mM 雷诺嗪可逆地缩短抽搐收缩 (TC) 的持续时间并消除后收缩。研究发现雷诺嗪与失活状态的 I(NaL) 钠通道的结合比与静息状态的 I(NaL) 的结合更紧密。
|
---|---|
体内研究 (In Vivo) |
在经历左冠状动脉前降支闭塞再灌注的大鼠中,雷诺嗪(推注 10 mg/kg 和输注 9.6 mg/kg/h;推注;持续 145 分钟;雄性 Wistar 大鼠)治疗可显着降低梗塞面积和心肌肌钙蛋白 T 释放[3]。
|
动物实验 |
Animal/Disease Models: Male Wistar rats (240-350 g)[3]
Doses: Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h) Route of Administration: Bolus injection; for 145 minutes Experimental Results: Dramatically decreased infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion. |
参考文献 |
[1]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.
[2]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. [3]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. |
分子式 |
C24H33N3O4
|
|
---|---|---|
分子量 |
427.54
|
|
CAS号 |
95635-55-5
|
|
相关CAS号 |
Ranolazine dihydrochloride;95635-56-6;Ranolazine-d3;1054624-77-9;Ranolazine-d5;1092804-87-9;Ranolazine-d8;1092804-88-0
|
|
SMILES |
O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3390 mL | 11.6948 mL | 23.3896 mL | |
5 mM | 0.4678 mL | 2.3390 mL | 4.6779 mL | |
10 mM | 0.2339 mL | 1.1695 mL | 2.3390 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02360397 | Completed Has Results | Drug: ranolazine | Ventricular Premature Complexes Myocardial Ischemia |
Kent Hospital, Rhode Island | December 2014 | Phase 2 |
NCT02252406 | Completed Has Results | Drug: Ranolazine Other: Placebo |
Stable Angina Metabolic Syndrome |
University of Florida | September 2015 | Phase 4 |
NCT02239926 | Terminated Has Results | Drug: Ranolazine Drug: Placebo |
Diarrhea Predominant Irritable Bowel Syndrome |
Mayo Clinic | September 2014 | Phase 2 Phase 3 |
NCT02133352 | Completed Has Results | Drug: Ranolazine | Pulmonary Hypertension Diastolic Left Ventricular Dysfunction |
Boston University | July 2011 | Phase 4 |
Stability of ML324 measured as percent composition of probe molecule in aqueous solution at r.t. over 48 hr in a) DPBS buffer (pH 7.4) b) JMJD2E AlphaScreen assay buffer (1 M HEPES buffer) c) pH 2 buffer and d) pH 10 buffer td> |
Concentration response curve of compound 1 (CID: 459617) in the AlphaScreen secondary assay td> |
Concentration response curve of ML324 (CID-44143209) in the AlphaScreen secondary assay td> |